Abiopharma

🔍 Reichman Amir (Director)

Company: Scinai Immunotherapeutics Ltd. (SCNI)

Report Date: 2026-06-16

Detailed Transactions and Holdings:

• Acquired 400,000,000 shares of Ordinary Shares (Direct)
  Date: 2026-06-16 | Code: A | equity_swap_involved: 0 | shares_owned_after: 711,637,600.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3

Footnotes:

• F1: The Ordinary Shares are no par value per share, and are represented by American Depositary Shares, each of which currently represents four thousand Ordinary Shares.
• F2: Includes 400,000,000 Ordinary Shares represented by restricted share units ("RSUs") granted on June 16, 2026, which vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through such dates.
• F3: Includes 71,637,600 Ordinary Shares represented by RSUs granted on January 25, 2024, of which 25% vested on the six-month anniversary thereof, 8.33% vested on the one-year anniversary thereof, and 66.66% vest in two equal annual installments thereafter, subject to the Reporting Person's continued service through such dates. Each RSU represents a contingent right to receive one Ordinary Share upon vesting.
• F4: Includes 240,000,000 Ordinary Shares represented by RSUs granted on December 22, 2025, which vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through such dates.